MAPT and Alzheimer disease: Glucagon-like peptide 1 analogues, which promote insulin secretion, may also act in many pathways related to AD, such as the reduction of amyloid-β and the impairment of neuronal function and cell death, as well as tau phosphorylation [58,59].